In summary, the combination may serve as a potential therapeutic strategy due to their ability to block the PD-1/PD-L1 pathway, increasing the number of tumor-infiltrating lymphocytes and decreasing PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.